{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:20:37Z","timestamp":1782782437329,"version":"3.54.5"},"reference-count":117,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"King\u2019s BHF Centre for Award Excellence","award":["RE\/18\/2\/34213"],"award-info":[{"award-number":["RE\/18\/2\/34213"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lupus anticoagulant (LA) is a well-established risk factor for the clinical manifestations of antiphospholipid syndrome (APS). Accurate LA detection is an essential prerequisite for optimal diagnosis and management of patients with APS or aPL carriers. Variability remains a challenge in LA testing, with reliable detection influenced by multiple factors, including pre-analytical conditions, anticoagulation treatment, choice of tests and procedures performed, as well as interpretation of results, that can lead to false-positives or negatives. A standardised approach to LA testing, following current guidance, based on published data and international consensus, and with attention to detail, is required to underpin accurate detection of LA. Future work should focus on better characterisation of the nature of LA, which may ultimately lead to improved diagnosis and management of patients with APS and aPL carriers. This article reviews current practice and challenges, providing an overview on detection of LA.<\/jats:p>","DOI":"10.1093\/rheumatology\/kead623","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T23:01:13Z","timestamp":1707260473000},"page":"SI54-SI63","source":"Crossref","is-referenced-by-count":5,"title":["Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-2845","authenticated-orcid":false,"given":"Maria","family":"Efthymiou","sequence":"first","affiliation":[{"name":"Department of Haematology, Cancer Institute, University College London , London, UK"},{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8623-139X","authenticated-orcid":false,"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[{"name":"Academic Department of Vascular Surgery, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-390X","authenticated-orcid":false,"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Cancer Institute, University College London , London, UK"},{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2024021703024302400_kead623-B1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B2","first-page":"621","article-title":"A haemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus","volume":"31","author":"Conley","year":"1952","journal-title":"J Clin Invest"},{"key":"2024021703024302400_kead623-B3","first-page":"75","article-title":"Acquired inhibitors of blood coagulation","volume":"1","author":"Feinstein","year":"1972","journal-title":"Prog Hemost Thromb"},{"key":"2024021703024302400_kead623-B4","first-page":"416","article-title":"Thrombosis in systemic lupus erythematosus despite circulating anticoagulants","volume":"62","author":"Bowie","year":"1963","journal-title":"J Lab Clin Med"},{"key":"2024021703024302400_kead623-B5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.0954-6820.1975.tb04897.x","article-title":"Intrauterine death and circulating anticoagulant (\u201cantithromboplastin\u201d)","volume":"197","author":"Nilsson","year":"1975","journal-title":"Acta Med Scand"},{"key":"2024021703024302400_kead623-B6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1471-0528.1981.tb02224.x","article-title":"\u201cLupus\u201d anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death","volume":"88","author":"Carreras","year":"1981","journal-title":"Br J Obstet Gynaecol"},{"key":"2024021703024302400_kead623-B7","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood.V81.10.2618.2618","article-title":"Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?","volume":"81","author":"Oosting","year":"1993","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B8","first-page":"629","volume":"66"},{"key":"2024021703024302400_kead623-B9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta(2)-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"de Laat","year":"2005","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B11","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)","volume":"125","author":"Gebhart","year":"2015","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024021703024302400_kead623-B13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B14","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","article-title":"Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review","volume":"122","author":"Garcia","year":"2013","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B16","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","article-title":"Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism","volume":"131","author":"Kearon","year":"2018","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B17","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"2024021703024302400_kead623-B19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024021703024302400_kead623-B20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024021703024302400_kead623-B21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort","volume":"49","author":"Radin","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024021703024302400_kead623-B22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203312446386","article-title":"Vitamin D and antiphospholipid syndrome","volume":"21","author":"Andreoli","year":"2012","journal-title":"Lupus"},{"key":"2024021703024302400_kead623-B23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2011.02.006","article-title":"The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis","volume":"128","author":"Abou-Nassar","year":"2011","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B24","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/aogs.13665","article-title":"The association between antiphospholipid antibodies and late fetal loss: a systematic review and meta-analysis","volume":"98","author":"Xu","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2024021703024302400_kead623-B25","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024021703024302400_kead623-B26","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2024021703024302400_kead623-B27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH06-05-0287","article-title":"Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity","volume":"96","author":"Ruffatti","year":"2006","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0961203320954520","article-title":"16th International congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome","volume":"29","author":"de Jes\u00fas","year":"2020","journal-title":"Lupus"},{"key":"2024021703024302400_kead623-B29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"key":"2024021703024302400_kead623-B30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","article-title":"Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2024021703024302400_kead623-B31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semarthrit.2012.03.011","article-title":"Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort","volume":"42","author":"Borowoy","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2024021703024302400_kead623-B32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-205159","article-title":"Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus","volume":"74","author":"Gustafsson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024021703024302400_kead623-B33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz-Irastorza","year":"2004","journal-title":"Arch Intern Med"},{"key":"2024021703024302400_kead623-B34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/keab307","article-title":"Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort","volume":"61","author":"Balbi","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024021703024302400_kead623-B35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B36","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ijlh.12234","article-title":"Antiphospholipid antibody testing and standardization","volume":"36","author":"Devreese","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"2024021703024302400_kead623-B38","doi-asserted-by":"crossref","first-page":"e12676","DOI":"10.1002\/rth2.12676","article-title":"Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants","volume":"6","author":"Favaloro","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2024021703024302400_kead623-B39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.autrev.2016.12.010","article-title":"Detection of lupus anticoagulant in the era of direct oral anticoagulants","volume":"16","author":"Hoxha","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2024021703024302400_kead623-B40","doi-asserted-by":"crossref","first-page":"12221","DOI":"10.1038\/s41598-020-69199-1","article-title":"Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants","volume":"10","author":"Reda","year":"2020","journal-title":"Sci Rep"},{"key":"2024021703024302400_kead623-B41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rth2.12264","article-title":"The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: can activated carbon eliminate false-positive results?","volume":"4","author":"De Kesel","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2024021703024302400_kead623-B42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pathol.2018.11.008","article-title":"Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives","volume":"51","author":"Favaloro","year":"2019","journal-title":"Pathology"},{"key":"2024021703024302400_kead623-B43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2007.05.006","article-title":"Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents","volume":"121","author":"Ten Boekel","year":"2007","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2009.09.001","article-title":"Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?","volume":"125","author":"Schouwers","year":"2010","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B45","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/0961203315583540","article-title":"When to screen for lupus anticoagulant? Influence of testing during acute phase and consequences for clinical practise","volume":"24","author":"Ruinemans-Koerts","year":"2015","journal-title":"Lupus"},{"key":"2024021703024302400_kead623-B46","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B47","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.jtha.2023.06.020","article-title":"Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"21","author":"Cohen","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2003-38897","article-title":"Hemostasis during normal pregnancy and puerperium","volume":"29","author":"Hellgren","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"2024021703024302400_kead623-B49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/humrep\/14.1.224","article-title":"Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome","volume":"14","author":"Topping","year":"1999","journal-title":"Hum Reprod"},{"key":"2024021703024302400_kead623-B50","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001580","article-title":"Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review","volume":"7","author":"Taha","year":"2021","journal-title":"RMD Open"},{"key":"2024021703024302400_kead623-B51","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.41425","article-title":"Antiphospholipid antibodies in critically Ill patients with COVID-19","volume":"72","author":"Xiao","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024021703024302400_kead623-B52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0033-1364185","article-title":"Recent guidelines and recommendations for laboratory detection of lupus anticoagulants","volume":"40","author":"Moore","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"2024021703024302400_kead623-B53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.thromres.2004.06.001","article-title":"Detection of procoagulant phospholipid interfering in tests for lupus anticoagulant","volume":"114","author":"Exner","year":"2004","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B54","volume-title":"CLSI Guideline CLSI document H60-A. Laboratory testing for the lupus anticoagulant; approved guideline.","author":"CLSI","year":"2014"},{"key":"2024021703024302400_kead623-B55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ijlh.12350","article-title":"Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory","volume":"37(Suppl 1)","author":"Gosselin","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"2024021703024302400_kead623-B56","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1515\/cclm-2011-0961","article-title":"Testing for lupus anticoagulants\u2014fresh or frozen?","volume":"50","author":"Froom","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"2024021703024302400_kead623-B57","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0042-1744363","article-title":"Testing for lupus anticoagulants","volume":"48","author":"Moore","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"2024021703024302400_kead623-B58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ijlh.12498","article-title":"Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STA-Compact-Max analyser","volume":"38","author":"Woolley","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"2024021703024302400_kead623-B59","first-page":"258","article-title":"Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia","volume":"39","author":"Lippi","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"2024021703024302400_kead623-B60","article-title":"Current controversies in lupus anticoagulant detection","volume":"5","author":"Moore","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"2024021703024302400_kead623-B61","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"key":"2024021703024302400_kead623-B63","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0028-1085481","article-title":"Laboratory testing for lupus anticoagulants: pre-examination variables, mixing studies, and diagnostic criteria","volume":"34","author":"Ledford-Kraemer","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"2024021703024302400_kead623-B64","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/jth.13020","article-title":"Mixing studies in lupus anticoagulant testing are required at least in some type of samples","volume":"13","author":"Devreese","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B65","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood-2009-09-244426","article-title":"Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants","volume":"115","author":"Devreese","year":"2010","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/MBC.0b013e328360c71b","article-title":"Lupus anticoagulant testing\u2014sometimes mixing is required: potential for false negatives without mixing studies","volume":"24","author":"Favaloro","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2024021703024302400_kead623-B67","author":"Clinical and Laboratory Standards Institute WPU","year":"2014"},{"key":"2024021703024302400_kead623-B68","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/j.1538-7836.2011.04440.x","article-title":"More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required","volume":"9","author":"Tripodi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0037-1614453","article-title":"dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies","volume":"81","author":"Pengo","year":"1999","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B70","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1055\/s-0037-1614164","article-title":"Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests","volume":"84","author":"Galli","year":"2000","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B71","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B72","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1365-2141.2002.03821.x","article-title":"Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods","volume":"119","author":"Jennings","year":"2002","journal-title":"Br J Haematol"},{"key":"2024021703024302400_kead623-B73","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1309\/AJCP4SPPLG5XVIXF","article-title":"Lupus anticoagulant testing: performance and practices by North American clinical laboratories","volume":"134","author":"Dembitzer","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2024021703024302400_kead623-B74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0033-1334864","article-title":"Measurement of lupus anticoagulants: an update on quality in laboratory testing","volume":"39","author":"Adams","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"2024021703024302400_kead623-B75","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.thromres.2006.10.015","article-title":"Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants","volume":"120","author":"Devreese","year":"2007","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B76","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1309\/AJCP3J1ZKYBFQXJM","article-title":"Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization","volume":"137","author":"Fritsma","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2024021703024302400_kead623-B77","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1373\/49.10.1608","article-title":"Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity","volume":"49","author":"Tripodi","year":"2003","journal-title":"Clin Chem"},{"key":"2024021703024302400_kead623-B78","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0037-1614601","article-title":"Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I","volume":"81","author":"Arnout","year":"1999","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B79","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2141.1994.tb04876.x","article-title":"Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin","volume":"87","author":"Arnout","year":"1994","journal-title":"Br J Haematol"},{"key":"2024021703024302400_kead623-B80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/jcp.47.6.497","article-title":"The Taipan snake venom time: a new test for lupus anticoagulant","volume":"47","author":"Rooney","year":"1994","journal-title":"J Clin Pathol"},{"key":"2024021703024302400_kead623-B81","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/jth.15438","article-title":"International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"Moore","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mbc.0000061283.28953.39","article-title":"The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants","volume":"14","author":"Moore","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2024021703024302400_kead623-B83","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MBC.0000000000000486","article-title":"Taipan snake venom time coupled with ecarin time enhances lupus anticoagulant detection in nonanticoagulated patients","volume":"27","author":"Moore","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2024021703024302400_kead623-B84","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1055\/s-0038-1649701","article-title":"The Textarin\/Ecarin ratio: a confirmatory test for lupus anticoagulants","volume":"70","author":"Triplett","year":"1993","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B85","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.25836","article-title":"Alternative assays to dRVVT and aPTT for lupus anticoagulant detection","volume":"95","author":"Moore","year":"2020","journal-title":"Am J Hematol"},{"key":"2024021703024302400_kead623-B86","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jth.14596","article-title":"Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository","volume":"17","author":"Efthymiou","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B87","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1515\/cclm-2018-0967","article-title":"Effect of an activated charcoal product (DOAC Stop\u2122) intended for extracting DOACs on various other APTT-prolonging anticoagulants","volume":"57","author":"Exner","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"2024021703024302400_kead623-B88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.13196","article-title":"The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays","volume":"42(Suppl 1)","author":"Exner","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"2024021703024302400_kead623-B89","doi-asserted-by":"crossref","first-page":"683357","DOI":"10.3389\/fmed.2021.683357","article-title":"A diagnostic solution for lupus anticoagulant testing in patients taking direct oral FXa inhibitors using DOAC filter","volume":"8","author":"Farkh","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024021703024302400_kead623-B90","doi-asserted-by":"crossref","first-page":"e12633","DOI":"10.1002\/rth2.12633","article-title":"Direct Oral Anticoagulant removal by a DOAC filter: impact on lupus anticoagulant testing\u2014evaluation on spiked and patient samples","volume":"6","author":"Linskens","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2024021703024302400_kead623-B91","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ijlh.13267","article-title":"Evaluation of DOAC filter, a new device to remove direct oral anticoagulants from plasma samples","volume":"42","author":"Sevenet","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"2024021703024302400_kead623-B92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2021.06.001","article-title":"Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection","volume":"204","author":"Tripodi","year":"2021","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B93","doi-asserted-by":"crossref","first-page":"e12648","DOI":"10.1002\/rth2.12648","article-title":"Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors","volume":"6","author":"White","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2024021703024302400_kead623-B94","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1055\/s-0037-1613259","article-title":"Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA","volume":"88","author":"Tripodi","year":"2002","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B95","first-page":"1511","article-title":"Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation","volume":"54","author":"Depreter","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2024021703024302400_kead623-B96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.thromres.2016.01.019","article-title":"Mixing test specific cut-off is more sensitive at detecting lupus anticoagulants than index of circulating anticoagulant","volume":"139","author":"Moore","year":"2016","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B97","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/rth2.12207","article-title":"Influence of anticardiolipin and anti-\u03b22 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification","volume":"3","author":"Vanoverschelde","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2024021703024302400_kead623-B98","author":"Clinical and Laboratory Standards Institute WPU","year":"2008"},{"key":"2024021703024302400_kead623-B99","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou","year":"2015","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B100","doi-asserted-by":"crossref","first-page":"1075121","DOI":"10.3389\/fcvm.2023.1075121","article-title":"Application of the thrombin generation assay in patients with antiphospholipid syndrome: a systematic review of the literature","volume":"10","author":"Gehlen","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2024021703024302400_kead623-B101","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1160\/TH08-06-0393","article-title":"Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography","volume":"101","author":"Devreese","year":"2009","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B102","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2024021703024302400_kead623-B103","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/rth2.12238","article-title":"Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: normal values and variability","volume":"3","author":"Calzavarini","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2024021703024302400_kead623-B104","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/jcm11082164","article-title":"Laboratory diagnosis of antiphospholipid syndrome: insights and hindrances","volume":"11","author":"Vandevelde","year":"2022","journal-title":"J Clin Med"},{"key":"2024021703024302400_kead623-B105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0038-1648480","article-title":"Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I","volume":"67","author":"Oostin","year":"1992","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2012-03-378646","article-title":"The significance of autoantibodies against \u03b22-glycoprotein I","volume":"120","author":"de Groot","year":"2012","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B107","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1182\/blood.V72.2.512.512","article-title":"Anti-prothrombin antibodies and the lupus anticoagulant","volume":"72","author":"Fleck","year":"1988","journal-title":"Blood"},{"key":"2024021703024302400_kead623-B108","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0040-1705115","article-title":"Antiphosphatidylserine\/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome","volume":"120","author":"Radin","year":"2020","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B109","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.imbio.2007.02.001","article-title":"Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?","volume":"212","author":"Bardin","year":"2007","journal-title":"Immunobiology"},{"key":"2024021703024302400_kead623-B110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1160\/TH12-07-0527","article-title":"Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS\/PT) in patients with and without lupus anticoagulant","volume":"109","author":"Bertolaccini","year":"2013","journal-title":"Thromb Haemost"},{"key":"2024021703024302400_kead623-B111","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.04.021","article-title":"Prevalence of aPhosphatidylserine\/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"214","author":"Zhu","year":"2022","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B112","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1515\/cclm-2021-0692","article-title":"Anti-phosphatidyl-serine\/prothrombin antibodies (aPS\/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?","volume":"59","author":"Tonello","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"2024021703024302400_kead623-B113","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.thromres.2018.11.003","article-title":"Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns","volume":"172","author":"Pengo","year":"2018","journal-title":"Thromb Res"},{"key":"2024021703024302400_kead623-B114","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fimmu.2019.00376","article-title":"Reliability of lupus anticoagulant and anti-phosphatidylserine\/prothrombin autoantibodies in antiphospholipid syndrome: a multicenter study","volume":"10","author":"Sciascia","year":"2019","journal-title":"Front Immunol"},{"key":"2024021703024302400_kead623-B115","doi-asserted-by":"crossref","first-page":"726820","DOI":"10.3389\/fimmu.2021.726820","article-title":"Antiphospholipid antibody assays in 2021: looking for a predictive value in addition to a diagnostic one","volume":"12","author":"Meroni","year":"2021","journal-title":"Front Immunol"},{"key":"2024021703024302400_kead623-B116","doi-asserted-by":"crossref","first-page":"100147","DOI":"10.1016\/j.labinv.2023.100147","article-title":"Associations among antiphospholipid antibody types, isotypes, and titers: an antiphospholipid syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study","volume":"103","author":"Gkrouzman","year":"2023","journal-title":"Lab Invest"},{"key":"2024021703024302400_kead623-B117","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0961203310361356","article-title":"Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice","volume":"19","author":"Roubey","year":"2010","journal-title":"Lupus"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/SI\/SI54\/56679683\/kead623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/SI\/SI54\/56679683\/kead623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:03:35Z","timestamp":1708139015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/SI\/SI54\/7601818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":117,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead623","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,2,1]]}}}